文献速递妇科

晚期低级别浆液性卵巢癌维持性激素治疗的成本效益

Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-10-06

本研究采用马尔可夫决策模型模拟47岁IIIC期低级别浆液性卵巢癌患者一线治疗后维持来曲唑对比观察的成本效益。结果显示维持来曲唑终身成本为69,985加元,增加0.91质量调整生命年和1.55生命年,增量成本效益比为每QALY 11,037加元,低于50,000加元/QALY的支付意愿阈值。

要点

  • 维持来曲唑较观察增加0.91 QALY和1.55生命年。
  • 增量成本效益比为每QALY 11,037加元,具成本效益。
  • 维持来曲唑组中位总生存150个月,观察组126个月。

核心结论

  • 在晚期低级别浆液性卵巢癌患者中,维持来曲唑是具成本效益的治疗策略,可改善QALY、生命年并减少复发。

研究设计与样本

  • 采用马尔可夫决策模型进行模拟决策分析,时间跨度为终身,基础病例为47岁IIIC期低级别浆液性卵巢癌患者,一线接受初次肿瘤细胞减灭术和辅助化疗后。
  • 分析两种策略:每日来曲唑维持治疗至疾病进展对比常规观察,从医疗支付方角度,成本以2018年加拿大元调整后报告。

主要发现

  • 维持来曲唑组终身成本为69,985加元(52,620美元),观察组成本未报告。
  • 维持来曲唑组较观察组增加0.91 QALY和1.55生命年。
  • 增量成本效益比为每QALY增加11,037加元(8,298美元)。
  • 模型估计中位总生存维持来曲唑组150个月,观察组126个月。
  • 维持来曲唑组5年和10年随访分别减少34%和17%的首次复发。

关键数值与推荐

  • 成本效益阈值设定为每QALY 50,000加元,增量成本效益比低于该阈值视为具成本效益。
  • 维持来曲唑的增量成本效益比为每QALY 11,037加元,低于50,000加元/QALY阈值。

临床怎么用

  • 对于晚期低级别浆液性卵巢癌患者,一线治疗后可考虑每日来曲唑维持治疗至疾病进展,以改善生存并减少复发,且具成本效益。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the cost-effectiveness of using maintenance hormonal therapy in patients with low grade serous ovarian cancer (LGSC). METHODS: A simulated decision analysis with a Markov decision model over a lifetime horizon was performed using the base case of a 47-year old patient with stage IIIC, LGSC following first-line treatment with primary cytoreductive surgery and adjuvant chemotherapy. Two treatment strategies were analyzed - maintenance daily letrozole until disease progression and routine observation. The analysis was from the perspective of the healthcare payer. Direct medical costs were estimated using public data sources and previous literature and were reported in adjusted 2018 Canadian dollars. The model estimated lifetime cost, quality-adjusted life years (QALY), life years (LY), median overall survival (OS), and number of recurrences with each strategy. Cost-effectiveness was compared using an incremental cost-effectiveness ratio (ICER). A strategy was considered cost-effective when the ICER was less than the willingness to pay (WTP) threshold of $50,000 CAD per QALY. Deterministic sensitivity analysis was performed to assess the impact of changing key clinical and cost variables. RESULTS: Maintenance letrozole was the preferred strategy with an associated lifetime cost of $69,985 CAD ($52,620 USD) and an observed improvement of 0.91 QALYs and 1.55 LYs. The ICER for letrozole maintenance therapy was an additional $11,037 CAD ($8298 USD) per QALY. The modeled median OS was 150 months with maintenance letrozole and 126 months in the observation strategy. The maintenance letrozole strategy resulted in 34% and 17% fewer first recurrences at 5-year and 10-year follow-up, respectively. CONCLUSION: Maintenance letrozole is a cost-effective treatment strategy in patients with advanced LGSC resulting in clinically-relevant improvement in QALYs, LYs, and fewer disease recurrences.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nica A, Lee JYJ, Hong NL, et al. Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer. Gynecol Oncol. 2020. PMID: 33032821. doi:10.1016/j.ygyno.2020.09.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。